Institute of Cancer Policy, Kings College London, London, United Kingdom.
Institute of Cancer Policy, Kings College London, London, United Kingdom; Evaluametrics Ltd., London, United Kingdom.
J Thorac Oncol. 2016 Jul;11(7):1040-50. doi: 10.1016/j.jtho.2016.03.010. Epub 2016 Mar 21.
Lung cancer is the leading cause of years of life lost because of cancer and is associated with the highest economic burden relative to other tumor types. Research remains at the cornerstone of achieving improved outcomes of lung cancer. We present the results of a comprehensive analysis of global lung cancer research between 2004 and 2013 (10 years).
The study used bibliometrics to undertake a quantitative analysis of research output in the 24 leading countries in cancer research internationally on the basis of articles and reviews in the Web of Science (WoS) database.
A total of 32,161 lung cancer research articles from 2085 different journals were analyzed. Lung cancer research represented only 5.6% of overall cancer research in 2013, a 1.2% increase since 2004. The commitment to lung cancer research has fallen in most countries apart from China and shows no correlation with lung cancer burden. A review of key research types demonstrated that diagnostics, screening, and quality of life research represent 4.3%, 1.8%, and 0.3% of total lung cancer research, respectively. The leading research types were genetics (20%), systemic therapies (17%), and prognostic biomarkers (16%). Research output is increasingly basic science, with a decrease in clinical translational research output during this period.
Our findings have established that relative to the huge health, social, and economic burden associated with lung cancer, the level of world research output lags significantly behind that of research on other malignancies. Commitment to diagnostics, screening, and quality of life research is much lower than to basic science and medical research. The study findings are expected to provide the requisite knowledge to guide future cancer research programs in lung cancer.
肺癌是导致癌症相关寿命损失的主要原因，与其他肿瘤类型相比，其经济负担最高。研究仍然是改善肺癌治疗效果的基石。我们呈现了 2004 年至 2013 年（10 年）全球肺癌研究的综合分析结果。
该研究采用文献计量学方法，基于 Web of Science（WoS）数据库中的文章和综述，对国际上 24 个癌症研究领先国家的癌症研究产出进行了定量分析。
共分析了来自 2085 种不同期刊的 32161 篇肺癌研究文章。2013 年，肺癌研究仅占所有癌症研究的 5.6%，比 2004 年增加了 1.2%。除中国外，大多数国家对肺癌研究的投入都在减少，且与肺癌负担无关。对关键研究类型的回顾表明，诊断、筛查和生活质量研究分别占肺癌研究的 4.3%、1.8%和 0.3%。主要的研究类型是遗传学（20%）、系统治疗学（17%）和预后生物标志物（16%）。研究产出越来越偏向基础科学，而这期间临床转化研究的产出有所下降。
我们的研究结果表明，与肺癌相关的巨大健康、社会和经济负担相比，世界研究产出水平明显滞后于其他恶性肿瘤的研究。对诊断、筛查和生活质量研究的投入远低于基础科学和医学研究。研究结果有望为指导未来肺癌癌症研究计划提供必要的知识。
